Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$133M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$93.9M |
| 4 |
Amazon
AMZN
|
+$91.8M |
| 5 |
Otis Worldwide
OTIS
|
+$84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$226M |
| 2 |
RTN
Raytheon Company
RTN
|
+$145M |
| 3 |
WBC
WABCO HOLDINGS INC.
WBC
|
+$51.2M |
| 4 |
Newmont
NEM
|
+$50.7M |
| 5 |
Yum! Brands
YUM
|
+$33.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.6% |
| 2 | Healthcare | 15.16% |
| 3 | Consumer Discretionary | 12.49% |
| 4 | Communication Services | 10.41% |
| 5 | Industrials | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PETQ
1851
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $1.55M | ﹤0.01% |
44,500
+5,900
| +15% | +$166K |
|
|
AIMT
1852
DELISTED
Aimmune Therapeutics
AIMT
| $1.55M | ﹤0.01% |
92,774
+19,100
| +26% | +$324K |
|
|
HSKA
1853
DELISTED
Heska Corp
HSKA
| $1.55M | ﹤0.01% |
16,600
+2,200
| +15% | +$170K |
|
1854
Vermilion Energy
VET
$1.72B
| $1.54M | ﹤0.01% |
349,067
+47,100
| +16% | +$222K |
|
|
CWEN.A
1855
DELISTED
Clearway Energy Class A
CWEN.A
| $1.54M | ﹤0.01% |
73,450
+6,300
| +9% | +$123K |
|
1856
Acco Brands
ACCO
$399M
| $1.54M | ﹤0.01% |
216,500
+28,000
| +15% | +$174K |
|
1857
OFG Bancorp
OFG
$2.26B
| $1.53M | ﹤0.01% |
114,700
+15,100
| +15% | +$182K |
|
1858
Gossamer Bio
GOSS
$83.3M
| $1.53M | ﹤0.01% |
117,900
+80,000
| +211% | +$1.01M |
|
1859
AAR Corp
AIR
$5.77B
| $1.53M | ﹤0.01% |
74,100
+9,500
| +15% | +$184K |
|
|
GTHX
1860
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $1.53M | ﹤0.01% |
63,100
+12,100
| +24% | +$200K |
|
1861
Alaunos Therapeutics
TCRT
$4.86M
| $1.53M | ﹤0.01% |
3,108
+408
| +15% | +$182K |
|
|
SAFE
1862
DELISTED
Safehold Inc.
SAFE
| $1.53M | ﹤0.01% |
26,600
+3,400
| +15% | +$186K |
|
|
SPNS
1863
DELISTED
Sapiens International
SPNS
| $1.53M | ﹤0.01% |
57,136
+8,587
| +18% | +$210K |
|
1864
Frontline
FRO
$9.02B
| $1.53M | ﹤0.01% |
221,427
+49,071
| +28% | +$417K |
|
1865
Shutterstock
SSTK
$217M
| $1.52M | ﹤0.01% |
43,600
+5,800
| +15% | +$209K |
|
1866
1st Source
SRCE
$2.13B
| $1.52M | ﹤0.01% |
42,789
+8,200
| +24% | +$272K |
|
1867
Unisys
UIS
$210M
| $1.52M | ﹤0.01% |
139,300
+18,300
| +15% | +$212K |
|
1868
Quince Therapeutics
QNCX
$33M
| $1.52M | ﹤0.01% |
+164
| New | +$1.5M |
|
|
TSE
1869
DELISTED
Trinseo
TSE
| $1.52M | ﹤0.01% |
68,400
-7,600
| -10% | -$156K |
|
1870
Marcus & Millichap
MMI
$1.2B
| $1.51M | ﹤0.01% |
52,500
+7,000
| +15% | +$197K |
|
1871
RadNet
RDNT
$6.08B
| $1.51M | ﹤0.01% |
95,400
+12,500
| +15% | +$181K |
|
|
VCRA
1872
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $1.51M | ﹤0.01% |
71,200
+10,100
| +17% | +$198K |
|
|
CBB
1873
DELISTED
Cincinnati Bell Inc.
CBB
| $1.51M | ﹤0.01% |
+101,600
| New | +$1.5M |
|
1874
ATN International
ATNI
$491M
| $1.51M | ﹤0.01% |
24,900
+3,200
| +15% | +$192K |
|
1875
ArcBest
ARCB
$3.28B
| $1.5M | ﹤0.01% |
56,700
+7,200
| +15% | +$154K |
|
Similar funds
Swiss National Bank's Q2 2020 Portfolio in Review
As of Q2 2020, Swiss National Bank held 2,599 positions worth $118B, up 26% from $94.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Swiss National Bank's Q2 2020 filing shows 119 new, 2,134 increased, 181 reduced and 161 closed positions. Its largest new stake was Otis Worldwide: 1,621,054 shares worth $92.2M. The largest sale was Allergan plc, an estimated $226M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q2 2020 buy was Otis Worldwide: 1,621,054 shares worth $92.2M.
- Swiss National Bank added most to Alibaba in Q2 2020, an estimated $133M increase.
- Swiss National Bank's biggest Q2 2020 reduction was Newmont, cutting an estimated $50.7M.
- Swiss National Bank fully exited Allergan plc in Q2 2020, selling an estimated $226M.
- Swiss National Bank's ten largest holdings make up 24% of its $118B portfolio in Q2 2020.
- Swiss National Bank opened 119 new positions and closed 161 in Q2 2020.
- Swiss National Bank's portfolio value rose 26% quarter-over-quarter to $118B.
Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.